Otonomy, Inc. Logo
Otonomy Reports Second Quarter 2016 Financial Results and Provides Corporate Update
04 août 2016 16h09 HE | Otonomy, Inc.
SAN DIEGO, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy, Inc. Logo
Otonomy to Present Results for AuriPro(TM) Phase 3 and OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
24 sept. 2015 07h30 HE | Otonomy, Inc.
SAN DIEGO, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere's Disease
09 sept. 2015 07h30 HE | Otonomy, Inc.
SAN DIEGO, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Appoints Dean Hakanson, M.D., as Chief Medical Officer
01 avr. 2015 07h00 HE | Otonomy, Inc.
SAN DIEGO, April 1, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Corporate Update
18 mars 2015 16h14 HE | Otonomy, Inc.
SAN DIEGO, March 18, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Corporate Update
12 mars 2015 08h00 HE | Otonomy, Inc.
SAN DIEGO, March 12, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Announces Closing of Follow-on Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
28 janv. 2015 16h02 HE | Otonomy, Inc.
SAN DIEGO, Jan. 28, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Announces Pricing of Follow-on Public Offering
22 janv. 2015 20h34 HE | Otonomy, Inc.
SAN DIEGO, Jan. 22, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Announces Launch of Follow-on Public Offering
21 janv. 2015 16h01 HE | Otonomy, Inc.
SAN DIEGO, Jan. 21, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Provides Corporate and Product Pipeline Update
08 janv. 2015 16h55 HE | Otonomy, Inc.
SAN DIEGO, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...